Gemtuzumab User Reviews & Ratings
Brand names: Mylotarg
Gemtuzumab has an average rating of 1.0 out of 10 from a total of 2 reviews on Drugs.com. 0% of reviewers reported a positive experience, while 100% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Acute Myeloid Leukemia | 2 reviews for Acute Myeloid Leukemia | 19 medications | |
| Add your review | |||
- golfer
- May 1, 2019
Mylotarg (gemtuzumab) for Acute Myeloid Leukemia "This is a medicine suggested for my sister who has only a few weeks to live. Will know tomorrow if Dr goes through with this. So scary. He did mentioned about it being taken off the market and now back available. How does one choose?"
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about gemtuzumab
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CD33 monoclonal antibodies
- Breastfeeding
- En español
Mylotarg (gemtuzumab) for Acute Myeloid Leukemia "This medicine should be taken off the market. It caused more harm than good. My mother died because of incompetent doctors and Mylotarg. Nothing was changed about the ingredients/composition of this medicine after the FDA approved it to be brought BACK on the market after being taken off for TEN years. It was taken off because it killed more than it saved. Just like it is still doing. The only thing about this medicine that changed when it was brought back in late 2017 was the dosage and how it is administered."